General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Novartis(SIGNIFICANT), Bayer Corporation US(MODEST), Boston Scientific(SIGNIFICANT), Boehringer Ingelheim Pharmaceuticals, Inc(MODEST), Merck & Co., Inc.(MODEST), Pfizer(MODEST), AstraZeneca Pharmaceuticals(MODEST), Amgen Inc.(MODEST), Cytokinetics(MODEST), Eli Lilly and Company(MODEST), Intellia(NONE), Novo Nordisk Inc.(SIGNIFICANT), Prolalio(MODEST) RESEARCH/RESEARCH GRANTS: AstraZeneca(SIGNIFICANT), Novartis(SIGNIFICANT), Verily(SIGNIFICANT), Merck & Co., Inc.(MODEST), American Regent(MODEST), Eli Lilly and Company(NONE), Amgen Inc.(NONE), Bayer Healthcare Pharmaceuticals(NONE), Boehringer Ingelheim Pharmaceuticals, Inc(MODEST), Novo Nordisk Inc.(NONE) OTHER FINANCIAL BENEFIT: Bristol-Myers Squibb Company (MODEST)

View Full Disclosure